delanzomib + lenalidomide + dexamethasone

A combination regimen consisting of **delanzomib** (CEP-18770, a proteasome inhibitor), **lenalidomide** (an immunomodulatory agent), and **dexamethasone** (a synthetic glucocorticoid corticosteroid), investigated for anti-myeloma effects, particularly in **multiple myeloma**. - **Delanzomib** inhibits the 20S proteasome, disrupting protein degradation and inducing apoptosis in malignant cells. - **Lenalidomide** is an immunomodulatory drug (IMiD) that induces tumor cell apoptosis, modulates the immune system, and inhibits angiogenesis. - **Dexamethasone** induces apoptosis through glucocorticoid receptor activation. Preclinical studies demonstrated that this triple combination results in superior tumor reduction and extended tumor growth delays over single agents or doublet regimens in multiple myeloma xenograft models[1][3][5].